home / stock / kdmn / kdmn quote
Last: | $3.395 |
---|---|
Change Percent: | -3.82% |
Open: | $3.47 |
Close: | $3.395 |
High: | $3.58 |
Low: | $3.32 |
Volume: | 1,334,624 |
Last Trade Date Time: | 10/26/2020 04:57:52 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.395 | $3.47 | $3.395 | $3.58 | $3.32 | 1,334,624 | 10-26-2020 |
$3.53 | $3.49 | $3.53 | $3.57 | $3.44 | 854,287 | 10-23-2020 |
$3.5 | $3.43 | $3.5 | $3.59 | $3.4 | 2,643,551 | 10-22-2020 |
$3.42 | $3.67 | $3.42 | $3.72 | $3.41 | 2,904,642 | 10-21-2020 |
$3.71 | $3.99 | $3.71 | $3.99 | $3.65 | 3,373,539 | 10-20-2020 |
$3.9 | $4.01 | $3.9 | $4.09 | $3.87 | 2,717,434 | 10-19-2020 |
$4 | $4.09 | $4 | $4.13 | $3.95 | 1,408,679 | 10-16-2020 |
$4.12 | $3.87 | $4.12 | $4.18 | $3.86 | 1,323,749 | 10-15-2020 |
$4.03 | $3.98 | $4.03 | $4.1 | $3.93 | 1,321,334 | 10-14-2020 |
$3.99 | $3.89 | $3.99 | $4.05 | $3.86 | 2,018,379 | 10-13-2020 |
$3.94 | $4.15 | $3.94 | $4.15 | $3.89 | 1,545,806 | 10-12-2020 |
$4.14 | $4.14 | $4.14 | $4.195 | $4.09 | 1,135,871 | 10-09-2020 |
$4.08 | $4.11 | $4.08 | $4.19 | $4.05 | 844,384 | 10-08-2020 |
$4.06 | $4.11 | $4.06 | $4.14 | $4.02 | 1,349,786 | 10-07-2020 |
$4.03 | $4.1 | $4.03 | $4.165 | $4.015 | 1,773,548 | 10-06-2020 |
$4.1 | $3.98 | $4.1 | $4.18 | $3.94 | 1,448,657 | 10-05-2020 |
$3.94 | $3.98 | $3.94 | $4.11 | $3.92 | 1,410,841 | 10-02-2020 |
$4.06 | $3.99 | $4.06 | $4.18 | $3.94 | 2,528,609 | 10-01-2020 |
$3.92 | $3.72 | $3.92 | $3.93 | $3.67 | 3,920,622 | 09-30-2020 |
$3.72 | $3.77 | $3.72 | $3.77 | $3.605 | 2,445,981 | 09-29-2020 |
News, Short Squeeze, Breakout and More Instantly...
Kadmon Holdings Inc. Company Name:
KDMN Stock Symbol:
NYSE Market:
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadm...
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kadmon Holdings, Inc. Skyrockets Amid Entering Definitive Merger Agreement with Sanofi Kadmon Holdings, Inc. (NASDAQ: KDMN) surged 73% in premarket trading after entering...